omega-n-methylarginine has been researched along with Hyperparathyroidism, Primary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrogini, E; Banti, C; Bernini, G; Carrara, D; Cetani, F; Ghiadoni, L; Giannarelli, C; Marcocci, C; Pinchera, A; Taddei, S; Virdis, A | 1 |
1 other study(ies) available for omega-n-methylarginine and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Female; Humans; Hyperparathyroidism, Primary; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Parathyroidectomy; Sulfaphenazole; Vasodilation | 2010 |